There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Anavex Life Sciences (AVXL – Research Report) and Curis (CRIS – Research Report) with bullish sentiments.
Anavex Life Sciences (AVXL)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Anavex Life Sciences, with a price target of $42.00. The company’s shares closed last Friday at $9.18, close to its 52-week low of $7.13.
According to TipRanks.com, Selvaraju has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Anavex Life Sciences with a $39.25 average price target.
See the top stocks recommended by analysts >>
Curis (CRIS)
H.C. Wainwright analyst Edward White reiterated a Buy rating on Curis today and set a price target of $16.00. The company’s shares closed last Friday at $0.74, close to its 52-week low of $0.70.
According to TipRanks.com, White is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Curis with a $11.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AVXL:
- Analysts Offer Insights on Technology Companies: WISeKey International Holding (WKEY) and Micron (MU)
- UR-Energy (URG) Gets a Buy from H.C. Wainwright
- Victoria Gold (VITFF) Receives a New Rating from H.C. Wainwright
- AquaBounty Technologies (AQB) Receives a Buy from H.C. Wainwright
- Reviva Pharmaceuticals to Present at the Lytham Partners Fall 2022 Investor Conference
